Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has scheduled an investor meeting on September 03, 2026, at its manufacturing facility in Doddaballapura, Bengaluru Rural District. The meeting will cover publicly available information, including the company's business overview, strategy, industry trends, and growth outlook. No unpublished price-sensitive information will be shared.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has published newspaper advertisements informing Shareholders about 19th Annual General Meeting of the Company scheduled to be held on September 23, 2026.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced an upgrade in its credit rating by India Ratings & Research (Ind-Ra) to IND A/Long-term rating upgraded and Positive/short-term rating affirmed for its bank loan facilities.

Onesource Specialty Pharma Ltd

OneSource Specialty Pharma Ltd has announced its Q1 FY27 earnings, with revenues at INR4,490 million, a 37% year-on-year growth, driven by the semaglutide commercial launch, new MSA contracts, and new customer wins. EBITDA has also grown 39% year-on-year and 34% sequentially.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd announces changes in senior management personnel (SMP) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Preeti Kalra is designated as SMP, and Ravi Kumar resigns from his position as Global Head – Injectables/ Head of Corporate Strategy, Portfolio & SPO.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced the publication of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has made the audio recording of its earnings call for Q1 FY27 available on its website, discussing unaudited financial results for the quarter ended June 30, 2026.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has allotted 2,900 equity shares under the OneSource ESOP 2021 to eligible employees upon exercise of vested options. The paid-up share capital of the company has increased from INR. 11,46,69,991/- to INR. 11,46,72,891/-.

Onesource Specialty Pharma Ltd

OneSource Specialty Pharma Ltd reported Q1FY27 results with revenue up 37% YoY and EBITDA up 39% YoY, driven by semaglutide commercialization and biologics growth.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced changes in its senior management personnel, with Preeti Kalra being designated as a Senior Management Personnel (SMP) effective July 24, 2026, and Ravi Kumar resigning from his position as Global Head – Injectables/ Head of Corporate Strategy, Portfolio & SPO, effective the same date.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced the outcome of its board meeting held on July 24, 2026, where the unaudited financial results for the quarter ended June 30, 2026, were approved. The results include a total revenue of Rs. 283.47 million, a total net loss after tax of Rs. 12.14 million, and other comprehensive income of Rs. 12.44 million. The financial results were reviewed by Deloitte Haskins & Sells, Chartered Accountants, and found to be in compliance with the Indian Accounting Standard and other accounting principles generally accepted in India.

Onesource Specialty Pharma Ltd

OneSource Specialty Pharma Ltd has scheduled its Earnings Call with analysts/investors on July 25, 2026, to discuss unaudited financial results for the quarter ended June 30, 2026.